Drug · DIN 02538121
MINT-BETAHISTINE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 20, 2023; first marketed October 20, 2023.
- Drug Identification Number (DIN)
- 02538121
- Company (DIN owner)
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Betahistine N07CA01
- Class
- Human
- Record last updated
- July 22, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BETAHISTINE HYDROCHLORIDE | 8 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 1, 2023: NOC 30891Abbreviated New Drug Submission (ANDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “mint-betahistine”. A notice may cover another product or only some lots: read it to see what it covers.
- Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone tablets recalled due to data integrity concernsJune 17, 2025 · Drugs · Product safety
- Mint-Betahistine 8, 16 & 24mg: Data integrity concerns with product's bioequivalence data that could lead to incorrect dosing.June 6, 2024 · Drugs · Product quality · Type I
Other DINs named MINT-BETAHISTINE
- DIN 02538148 · Marketed
- DIN 02538156 · Marketed